Rapid virologic response: a new milestone in the management of chronic hepatitis C.

PubWeight™: 1.33‹?› | Rank: Top 10%

🔗 View Article (PMID 18171217)

Published in Clin Infect Dis on January 01, 2008

Authors

Fred Poordad1, K Rajender Reddy, Paul Martin

Author Affiliations

1: Hepatology and Liver Transplantation, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA. Fred.Poordad@cshs.org

Articles citing this

IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. J Infect Dis (2011) 1.33

Chronic hepatitis B: what should be the goal for new therapies? Antiviral Res (2013) 1.12

Hepatitis C virus and alcohol. Semin Liver Dis (2009) 1.08

Second-generation Cobas AmpliPrep/Cobas TaqMan HCV quantitative test for viral load monitoring: a novel dual-probe assay design. J Clin Microbiol (2012) 1.06

Monitoring during and after antiviral therapy for hepatitis B. Hepatology (2009) 0.91

Effects of host and virus related factors on interferon-α+ribavirin and pegylated-interferon+ribavirin treatment outcomes in chronic Hepatitis C patients. Virol J (2011) 0.88

Plasma ribavirin trough concentrations at week 4 predict hepatitis C virus (HCV) relapse in HIV-HCV-coinfected patients treated for chronic hepatitis C. Antimicrob Agents Chemother (2010) 0.84

In the clinic. Hepatitis C. Ann Intern Med (2008) 0.84

Optimal duration of treatment for HCV genotype 1 infection in slow responders: a meta-analysis. Hepat Mon (2011) 0.81

Significance of a reduction in HCV RNA levels at 4 and 12 weeks in patients infected with HCV genotype 1b for the prediction of the outcome of combination therapy with peginterferon and ribavirin. BMC Infect Dis (2012) 0.81

Determining hepatitis C virus genotype distribution among high-risk groups in Iran using real-time PCR. World J Gastroenterol (2014) 0.81

High ability to predict the treatment outcome of peginterferon and ribavirin combination therapy based on the reduction in HCV RNA levels at 4 weeks after starting therapy and amino acid substitutions in the hepatitis C virus in patients infected with HCV genotype 1b. J Gastroenterol (2010) 0.80

The role of consensus interferon in the current treatment of chronic hepatitis C viral infection. Gastroenterol Hepatol (N Y) (2008) 0.79

Efficacy of 24-week pegylated interferon alpha and ribavirin combination therapy in highly selected patients infected with hepatitis C virus genotype 1. Hepat Mon (2015) 0.79

Prediction of sustained virologic responses to combination therapy of pegylated interferon-α and ribavirin in patients with chronic hepatitis C infection. J Family Community Med (2013) 0.78

Chronic hepatitis C genotype 1 virus: who should wait for treatment? World J Gastroenterol (2014) 0.78

Host-based ribavirin resistance influences hepatitis C virus replication and treatment response. J Virol (2011) 0.78

Hepatitis C virus (HCV) genotype 2a has a better virologic response to antiviral therapy than HCV genotype 1b. Int J Clin Exp Med (2015) 0.77

Rapid virological response to peginterferon alfa and ribavirin treatment of chronic hepatitis C predicts sustained virological response and relapse in genotype 1 patients. Therap Adv Gastroenterol (2009) 0.77

Immediate virological response predicts the success of short-term peg-interferon monotherapy for chronic hepatitis C. World J Gastroenterol (2010) 0.76

On-treatment predictions of success in peg-interferon/ribavirin treatment using a novel formula. World J Gastroenterol (2010) 0.75

Response to Pegylated Interferon Plus Ribavirin in Patients with Hepatitis C Virus Genotype 6a Infection from Guangdong and Guangxi Province of China. Gastroenterol Res Pract (2016) 0.75

Importance of virological response in the early stage of telaprevir-based triple therapy for hepatitis C. World J Hepatol (2015) 0.75

Rapid virological response of telaprevir and boceprevir in a Brazilian cohort of HCV genotype 1 patients: a multicenter longitudinal study. Ther Clin Risk Manag (2017) 0.75

Articles by these authors

(truncated to the top 100)

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55

National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant (2005) 19.83

Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01

Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93

Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med (2013) 13.30

Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature (2010) 12.27

Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet (2010) 9.90

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med (2014) 9.45

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med (2014) 9.25

Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol (2002) 8.21

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med (2014) 7.73

ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med (2014) 4.90

Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology (2008) 4.73

hORFeome v3.1: a resource of human open reading frames representing over 10,000 human genes. Genomics (2007) 4.62

Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50

High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat Genet (2012) 4.46

Differentiation of the major Listeria monocytogenes serovars by multiplex PCR. J Clin Microbiol (2004) 4.32

Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med (2009) 4.21

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther (2007) 4.16

Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant (2006) 4.09

Wound healing recapitulates morphogenesis in Drosophila embryos. Nat Cell Biol (2002) 4.04

Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology (2006) 3.92

Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. Nat Genet (2009) 3.52

Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology (2004) 3.47

Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood (2002) 3.45

Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med (2009) 3.41

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis (2013) 3.30

Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med (2015) 3.13

Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol (2005) 3.10

Live imaging of innate immune cell sensing of transformed cells in zebrafish larvae: parallels between tumor initiation and wound inflammation. PLoS Biol (2010) 2.99

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol (2008) 2.97

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology (2004) 2.97

Randomized study comparing banding and propranolol to prevent initial variceal hemorrhage in cirrhotics with high-risk esophageal varices. Gastroenterology (2005) 2.90

Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med (2005) 2.68

Dense genotyping of immune-related disease regions identifies 14 new susceptibility loci for juvenile idiopathic arthritis. Nat Genet (2013) 2.60

c-Jun regulates eyelid closure and skin tumor development through EGFR signaling. Dev Cell (2003) 2.59

The role of social scientists in synthetic biology. Science & Society Series on Convergence Research. EMBO Rep (2009) 2.57

Wound repair at a glance. J Cell Sci (2009) 2.53

First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline. J Viral Hepat (2002) 2.43

Live imaging of wound inflammation in Drosophila embryos reveals key roles for small GTPases during in vivo cell migration. J Cell Biol (2005) 2.38

New aspects regarding evolution and virulence of Listeria monocytogenes revealed by comparative genomics and DNA arrays. Infect Immun (2004) 2.31

Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial. JAMA (2012) 2.29

Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology (2014) 2.28

Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology (2006) 2.22

An explicit quality indicator set for measurement of quality of care in patients with cirrhosis. Clin Gastroenterol Hepatol (2010) 2.18

Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol (2003) 2.18

Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology (2004) 2.17

Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. Ann Intern Med (2015) 2.13

Dynamic analysis of dorsal closure in Drosophila: from genetics to cell biology. Dev Cell (2002) 2.06

Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology (2010) 2.06

Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. Gastroenterology (2006) 2.05

Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology (2014) 2.04

Treatment of hepatitis C after kidney transplant: a pooled analysis of observational studies. J Med Virol (2014) 2.03

Dynamic analysis of filopodial interactions during the zippering phase of Drosophila dorsal closure. Development (2008) 2.03

Molecular mechanisms linking wound inflammation and fibrosis: knockdown of osteopontin leads to rapid repair and reduced scarring. J Exp Med (2008) 1.99

Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology (2005) 1.97

Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl (2004) 1.95

6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology (2003) 1.95

Wound healing and inflammation: embryos reveal the way to perfect repair. Philos Trans R Soc Lond B Biol Sci (2004) 1.94

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol (2006) 1.92

Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology (2014) 1.91

Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology (2015) 1.87

Renal function after orthotopic liver transplantation is predicted by duration of pretransplantation creatinine elevation. Liver Transpl (2005) 1.87

The North American Study for the Treatment of Refractory Ascites. Gastroenterology (2003) 1.87

Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report. Biol Blood Marrow Transplant (2006) 1.86

Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2005) 1.85

Overlapping genetic susceptibility variants between three autoimmune disorders: rheumatoid arthritis, type 1 diabetes and coeliac disease. Arthritis Res Ther (2010) 1.85

The inflammation-fibrosis link? A Jekyll and Hyde role for blood cells during wound repair. J Invest Dermatol (2007) 1.85

Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology (2014) 1.83

Live imaging of tumor initiation in zebrafish larvae reveals a trophic role for leukocyte-derived PGE₂. Curr Biol (2012) 1.80

Imaging macrophage chemotaxis in vivo: studies of microtubule function in zebrafish wound inflammation. Cell Motil Cytoskeleton (2006) 1.79

Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study. Pharmacoepidemiol Drug Saf (2011) 1.76

The pharmaceuticalisation of society? A framework for analysis. Sociol Health Illn (2011) 1.75

Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end-stage liver disease (NACSELD) experience. Hepatology (2012) 1.74

Molecular caving. Curr Biol (2003) 1.73

Lack of benefit of pre-transplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era. Liver Transpl (2006) 1.72

Prevalence and significance of occult hepatitis B in a liver transplant population with chronic hepatitis C. Liver Transpl (2008) 1.72

Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology (2007) 1.72

Endoscopic management of biliary complications after adult living donor liver transplantation. Am J Gastroenterol (2004) 1.68

Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Ann Intern Med (2014) 1.64

Structures in focus--filopodia. Int J Biochem Cell Biol (2002) 1.63

Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. Gastroenterology (2013) 1.63

Dynamic analysis of actin cable function during Drosophila dorsal closure. Curr Biol (2002) 1.62

Immune dysfunction and infections in patients with cirrhosis. Clin Gastroenterol Hepatol (2011) 1.61

Comparison of clinical outcomes in chronic hepatitis B liver transplant candidates with and without hepatocellular carcinoma. Liver Transpl (2007) 1.61

Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl (2007) 1.58

Transplantation: impact of pretransplant renal insufficiency. Liver Transpl (2008) 1.58

Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a. Liver Int (2008) 1.56

Identification of AF4/FMR2 family, member 3 (AFF3) as a novel rheumatoid arthritis susceptibility locus and confirmation of two further pan-autoimmune susceptibility genes. Hum Mol Genet (2009) 1.55

Nuclear gene sequences from a late pleistocene sloth coprolite. Curr Biol (2003) 1.55

A multicenter pilot evaluation of the National Institutes of Health chronic graft-versus-host disease (cGVHD) therapeutic response measures: feasibility, interrater reliability, and minimum detectable change. Biol Blood Marrow Transplant (2011) 1.54

Hepatitis C infection and the patient with end-stage renal disease. Hepatology (2002) 1.53

Risk of waitlist mortality in patients with primary sclerosing cholangitis and bacterial cholangitis. Liver Transpl (2013) 1.52

Epigenetic reprogramming during wound healing: loss of polycomb-mediated silencing may enable upregulation of repair genes. EMBO Rep (2009) 1.51

Prioritization of competing damage and developmental signals by migrating macrophages in the Drosophila embryo. Curr Biol (2010) 1.51

Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology (2006) 1.50

Calcium flashes orchestrate the wound inflammatory response through DUOX activation and hydrogen peroxide release. Curr Biol (2013) 1.50

Association between proton pump inhibitor use and spontaneous bacterial peritonitis. Dig Dis Sci (2007) 1.50

Influence of alcohol use, race, and viral coinfections on spontaneous HCV clearance in a US veteran population. Hepatology (2004) 1.49

Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis. Am J Gastroenterol (2007) 1.49